Navigation Links
Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients
Date:3/3/2010

REHOVOT, Israel, and SAN DIEGO, California, March 3, 2010 /PRNewswire/ -- Foamix Ltd., (Foamix), a leading developer of topical foams for dermatological and gynecological use, and Therapeutics Inc. (TI), an innovative drug development company, announced today a joint venture that will focus on developing new prescription medicated foam formulations and demonstrating their safety and efficacy.

The partnership will accelerate the development of value-added foam formulations for the treatment of common skin inflammation conditions, such as atopic dermatitis and psoriasis, which inflict more than 20 million Americans, as well as seborrheic dermatitis and allergic skin reactions.

"It is with enthusiastic anticipation that we enter into our partnership with Therapeutics Inc, a dynamic company that can move promising topical drugs through preclinical and clinical studies into the marketplace," said Dr. Dov Tamarkin, CEO of Foamix. "What we are creating through this joint venture is a powerful development engine that will leverage our respective expertise and resources to drive new products to market."

"Foamix has a proven track record of successfully marrying their proprietary and unique foam systems with dermatological drugs. Together we will develop unique Rx foams that can be readily applied to the sensitive skin of atopic dermatitis and psoriasis patients. These products will fill an unmet market need for convenient and elegant treatments of inflammatory skin diseases," said Daniel Piacquadio, M.D, President & CEO of Therapeutics Inc, as he announced the joint development agreement.

About Foamix

Foamix Ltd. is a leading developer of topical and mucosal foams for dermatological and gynecological applications. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with pharmaceutical and cosmetic companies on a range of projects in the development of proprietary dermatological and gynecologic foam products. Additionally, the Company has an in-house pipeline of dermatological and gynecological formulations in foam presentation. Foamix's psoriasis foam product licensed to Dr. Reddy's Laboratories and marketed by Promius Pharma under the trade mark Scytera(TM) was launched in the United States in early 2009.

Foamix has nineteen issued patents worldwide covering its foam and OilGel technology platforms and over 150 pending applications of which more than 60 are filed in the United States.

About Therapeutics, Inc

Therapeutics, Inc. (TI) is a drug development company focused on developing innovative treatments for cutaneous and mucosal diseases. TI provides unwavering service and moves products from concept to the bench top, to proof-of-concept and then, as appropriate, through clinical development with regulatory review and approval. TI evaluates and integrates clinical, regulatory, technology, market and competitive factors to develop best-of-class dermatology solutions.

    For additional information please see http://www.therapeuticsinc.com

    Media Contact: Denise Dwyer, Therapeutics, Inc.
    Phone: +1-858-571-1800 x106
    E-mail: media@therapeuticsinc.com

    For additional information please see http://www.foamix.co.il

    Media contact: Sigal Maymon, Foamix Ltd.
    Phone: +972-8-9316233
    E-mail: info@foamix.co.il

SOURCE Foamix Ltd

Back to top
'/>"/>
SOURCE Foamix Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
2. Foamix Signs Term Sheet to Acquire License to Organo-Boron Antifungal Molecules - Will Target the $11 Billion Dollars Fungal Infection Market
3. Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis
4. Foamix Receives US Patent on Novel Foam Technology
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 2016   ViaCyte, Inc ., a leading, ... stem cell-derived islet replacement therapy for the treatment ... announced that ViaCyte and Janssen Biotech, Inc., one ... Johnson, have agreed to consolidate the assets of ... provides ViaCyte with an exclusive license to all ...
(Date:2/3/2016)... Mass., Feb. 3, 2016 Harvard Apparatus ... biotechnology company developing bioengineered organ implants for life-threatening ... announced that CEO Jim McGorry , will ... Conference on Tuesday, February 9, 2016 at ... City . HART,s presentation will be webcast ...
(Date:2/3/2016)... ... February 03, 2016 , ... StarNet Communications ... solutions today announced the addition of a powerful “Session Preview” feature to its ... current state of the remote Linux desktop or other applications (sessions) they have ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... aid in the rapid development and ongoing quality control of molecular assays targeting ... is extremely high,” Dr. Gregory R. Chiklis, President and CEO of ZeptoMetrix, relayed ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
Breaking Biology News(10 mins):